|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRPC4 |
Gene summary for TRPC4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRPC4 | Gene ID | 7223 |
| Gene name | transient receptor potential cation channel subfamily C member 4 | |
| Gene Alias | HTRP-4 | |
| Cytomap | 13q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | Q9UBN4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7223 | TRPC4 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.82e-05 | 2.43e-01 | -0.0811 |
| 7223 | TRPC4 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.80e-02 | 1.21e-01 | -0.1954 |
| 7223 | TRPC4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.76e-02 | 1.69e-01 | -0.1207 |
| 7223 | TRPC4 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.55e-07 | 2.13e-01 | -0.1464 |
| 7223 | TRPC4 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.01e-05 | 1.12e-01 | -0.1001 |
| 7223 | TRPC4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.10e-06 | 2.27e-01 | -0.059 |
| 7223 | TRPC4 | P16T-E | Human | Esophagus | ESCC | 7.66e-49 | 8.11e-01 | 0.1153 |
| 7223 | TRPC4 | P54T-E | Human | Esophagus | ESCC | 4.66e-30 | 5.39e-01 | 0.0975 |
| 7223 | TRPC4 | P56T-E | Human | Esophagus | ESCC | 7.62e-17 | 1.37e+00 | 0.1613 |
| 7223 | TRPC4 | P62T-E | Human | Esophagus | ESCC | 6.84e-53 | 8.70e-01 | 0.1302 |
| 7223 | TRPC4 | P80T-E | Human | Esophagus | ESCC | 2.86e-35 | 7.69e-01 | 0.155 |
| 7223 | TRPC4 | P89T-E | Human | Esophagus | ESCC | 2.90e-30 | 1.17e+00 | 0.1752 |
| 7223 | TRPC4 | P104T-E | Human | Esophagus | ESCC | 8.26e-10 | 5.14e-01 | 0.0931 |
| 7223 | TRPC4 | P130T-E | Human | Esophagus | ESCC | 5.53e-63 | 9.88e-01 | 0.1676 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
| GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
| GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
| GO:004316126 | Esophagus | HGIN | proteasome-mediated ubiquitin-dependent protein catabolic process | 114/2587 | 412/18723 | 7.00e-14 | 1.20e-11 | 114 |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
| GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
| GO:00224043 | Esophagus | ESCC | molting cycle process | 53/8552 | 84/18723 | 9.62e-04 | 4.88e-03 | 53 |
| GO:00224053 | Esophagus | ESCC | hair cycle process | 53/8552 | 84/18723 | 9.62e-04 | 4.88e-03 | 53 |
| GO:0001942 | Esophagus | ESCC | hair follicle development | 51/8552 | 81/18723 | 1.27e-03 | 6.14e-03 | 51 |
| GO:0098773 | Esophagus | ESCC | skin epidermis development | 53/8552 | 85/18723 | 1.43e-03 | 6.77e-03 | 53 |
| GO:00423033 | Esophagus | ESCC | molting cycle | 64/8552 | 107/18723 | 2.24e-03 | 9.85e-03 | 64 |
| GO:00426333 | Esophagus | ESCC | hair cycle | 64/8552 | 107/18723 | 2.24e-03 | 9.85e-03 | 64 |
| GO:00488201 | Esophagus | ESCC | hair follicle maturation | 11/8552 | 13/18723 | 4.76e-03 | 1.85e-02 | 11 |
| GO:00487092 | Esophagus | ESCC | oligodendrocyte differentiation | 55/8552 | 95/18723 | 1.10e-02 | 3.72e-02 | 55 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRPC4 | SNV | Missense_Mutation | c.2848C>G | p.Pro950Ala | p.P950A | Q9UBN4 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.954) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| TRPC4 | SNV | Missense_Mutation | c.2365N>A | p.Glu789Lys | p.E789K | Q9UBN4 | protein_coding | tolerated(0.73) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRPC4 | SNV | Missense_Mutation | rs75129764 | c.50N>A | p.Arg17His | p.R17H | Q9UBN4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRPC4 | SNV | Missense_Mutation | c.1660N>A | p.Cys554Ser | p.C554S | Q9UBN4 | protein_coding | tolerated(0.11) | probably_damaging(0.985) | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TRPC4 | SNV | Missense_Mutation | c.1156N>T | p.His386Tyr | p.H386Y | Q9UBN4 | protein_coding | deleterious(0.04) | benign(0.439) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| TRPC4 | SNV | Missense_Mutation | c.1798A>T | p.Met600Leu | p.M600L | Q9UBN4 | protein_coding | deleterious(0.05) | possibly_damaging(0.743) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TRPC4 | SNV | Missense_Mutation | novel | c.643N>C | p.Asp215His | p.D215H | Q9UBN4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
| TRPC4 | SNV | Missense_Mutation | c.71N>A | p.Arg24Lys | p.R24K | Q9UBN4 | protein_coding | deleterious(0.03) | probably_damaging(0.969) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| TRPC4 | SNV | Missense_Mutation | c.1273N>A | p.Gly425Arg | p.G425R | Q9UBN4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1OY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TRPC4 | SNV | Missense_Mutation | novel | c.466G>A | p.Glu156Lys | p.E156K | Q9UBN4 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | blocker | 381744969 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | blocker | 381744967 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | blocker | 135651058 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | activator | 252166584 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | blocker | 381744972 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | blocker | 135649695 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | TRPC4 and TRPC5 inhibitor | |||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | blocker,activator | 135652740 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | blocker | 178101072 | ||
| 7223 | TRPC4 | ION CHANNEL, KINASE, DRUGGABLE GENOME, CELL SURFACE | activator | 381744968 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |